Showing 8261-8270 of 20417 results for "".
In and Around HDL
https://reachmd.com/programs/lipid-luminations/in-and-around-hdl/2173/Dr. Larry Kaskel welcomes Dr. Daniel Rader to Lipid Luminations. Dr. Rader is Professor of Medicine, Pharmacology, and Pathology and Laboratory Medicine at University of Pennsylvania. He is the Director of Preventive Cardiovascular Medicine and Lipid Clinic Director at General Clinical Research CentC3: Grass Roots Fight to Stop Colorectal Cancer
https://reachmd.com/programs/clinicians-roundtable/c3-grass-roots-fight-to-stop-colorectal-cancer/1866/In this segment host Dr. Larry Kaskel speaks with President of the Colorectal Cancer Coalition, Carlea Bauman about their grass roots efforts to fight colorectal cancer. Learn about their latest campaign to Cover Your Butt which encourages legislation to cover all Americans threatened by colorectalRestless Legs Syndrome
https://reachmd.com/programs/clinicians-roundtable/restless-legs-syndrome/1720/Restless Legs Syndrome (RLS) is a neurologic movement and sleep disorder characterized by sensory and motor abnormalities that are frequently misdiagnosed. There is a compelling urge to move the legs in association with unusual or uncomfortable sensations, which become obvious or worse during periodOverview of Early Parkinson’s Disease
https://reachmd.com/programs/clinicians-roundtable/overview-of-early-parkinsons-disease/1716/Parkinson's disease is a neurodegenerative disease that causes motor (movement) and nonmotor symptoms, such as tremor, slowed movements and stiffness, as well as many other symptoms. While Parkinson’s typically manifests when a person is age 50 or 60 it can begin as early as age 30. Host Dr. LeslieThe Future of Anthrax Research and Defense
https://reachmd.com/programs/focus-on-disaster-medicine-and-preparedness/the-future-of-anthrax-research-and-defense/1366/Is anthrax becoming an obsolete weapon? Biotechnology has changed the face of medical research. In developing defenses against anthrax, advances in genomics and proteonomics have suggested new approaches. Perhaps the days of weaponized anthrax are numbered. Join Dr. Nicholas Bergman as he discussesEmergencies at 30,000 Feet: Ground Support
https://reachmd.com/programs/clinicians-roundtable/emergencies-at-30000-feet-ground-support-1-1/1157/You're a healthcare professional and you've just answered the call to help a sick airline passenger while cruising at 30,000 feet. No resources; no support staff; no emergency landing for another 1/2 hour. No problem! You know what to do because you listen to boonDOCS Medicine... Tune in with DrComplications of Vesicovaginal Fistulas
https://reachmd.com/programs/clinicians-roundtable/complications-of-vesicovaginal-fistulas/697/In this segment, Dr. Wall describes some of the serious, and sadly oftentimes fatal complications and comorbidities arising secondary to developing vesicovaginal fistulas in the postpartum period. He then contrasts the rates of these potential outcomes in women living in the United States vs. develoMedicine for the Masses?
https://reachmd.com/programs/clinicians-roundtable/medicine-for-the-masses/497/Pamela Fadem speaks about the Hesperian Foundation's publishings in the "Where There Are No Doctors" series. This proposed village handbook has sold over three million copies and has been translated into 50 languages. It is used by shopkeepers, pharmacists, teachers, health workers, mothers and midwPost-BCMA Treatment Selection in R/R Multiple Myeloma
https://reachmd.com/programs/project-oncology/post-bcma-treatment-myeloma/54831/This is a non-certified educational series produced and controlled by ReachMD. As BCMA-directed therapies move into earlier lines of care, more patients with relapsed and refractory (R/R) multiple myeloma are entering a treatment space with limited consensus on optimal sequencing strategies. In thisEnhancing HCC Outcomes Through Multidisciplinary Care
https://reachmd.com/programs/project-oncology/enhancing-hcc-outcomes-through-multidisciplinary-care/26252/Explore best practices for taking a multidisciplinary approach to hepatocellular carcinoma management.